|
Fast Forward Speeding Treatments to People with MS. Fast Forward, LLC and Apitope International NV Announce $1 Million Partnership for Development of ATX-MS-1467 Vaccine for MS
Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the gap between research and drug development, has announced a partnership to support Apitope International NV, the autoimmune peptide therapy company, in its proof of principle clinical trial of ATX-MS-1467. This peptide therapeutic vaccine is designed to target and prevent the abnormal pathological immune response in multiple sclerosis (MS).
|
|
|
